Efficacy/ Safety of Omalizumab in Patients With Seasonal Allergic Asthma and Seasonal Allergic Rhinoconjunctivitis

Exclusion Criteria

• •Females of childbearing potential: pregnancy, birth control,breast-feeding
• •Concurrent diseases/conditions and history of other diseases/conditions
• •1. patients who have a positive history of significant clinical manifestations of allergy as a result of sensitization against tree pollen allergens, weed allergens and perennial allergens (e.g. Aspergillus spores, animal dander, house dust mite).
• •2. patients with a history of food or drug related severe anaphylactoid or anaphylactic reaction(s).
• •Ingredient hypersensitivity
• •1. patients with known hypersensitivity to any ingredients, including excipients (sucrose, histidine, polysorbate 20) of the study medication, any immunotherapy, or drugs related to Omalizumab (e.g., monoclonal antibodies, polyclonal gamma globulin).
• •2. patients with hypersensitivity to the trail's asthma rescue- or escalation-medication or related drugs.